OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
MWN-AI** Summary
OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED), has secured $1.4 million in non-dilutive funding. This funding enhances the company's capacity to progress its innovative pipeline while safeguarding shareholder equity. OKYO Pharma's lead program, OK-101, is designed to address the unmet medical need associated with NCP, a debilitating condition currently lacking FDA-approved treatment options.
Dr. Gary S. Jacob, CEO of OKYO Pharma, emphasized the significance of this funding in advancing their mission to develop impactful ophthalmic therapies. He reiterated that the financial support will facilitate the company's commitment to creating shareholder value while pushing forward clinical programs aimed at improving patient outcomes.
NCP is marked by severe eye, face, or head pain, often resulting from nerve damage and inflammation in the cornea. Presently, it is managed through off-label use of topical and systemic treatments since there is no approved drug specifically for NCP.
OK-101, infused with a lipid anchor to extend its ocular residence time, has shown promise in preclinical and recent Phase 2 studies. It demonstrated statistical significance in multiple efficacy endpoints for treating DED and is undergoing further evaluation in a Phase 2 trial for NCP.
OKYO Pharma's strategic focus on research and fiscal responsibility positions it well within the multi-billion-dollar dry eye market while addressing critical unmet needs in ocular health. For more information, visit OKYO’s website at www.okyopharma.com.
MWN-AI** Analysis
OKYO Pharma's recent announcement of securing $1.4 million in non-dilutive funding presents a significant opportunity for investors, particularly given the company's focus on addressing unmet medical needs in the ophthalmic space. The funding will primarily support the advancement of its lead program, OK-101, aimed at treating neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). The absence of FDA-approved therapies for NCP highlights both the critical nature of this condition and the market potential for OKYO’s innovative solutions.
Investors should view this development as a positive signal of financial health and management's commitment to enhancing shareholder value without dilution. This is particularly crucial for clinical-stage companies which often face substantial funding challenges. The strategic allocation of funds toward OK-101 positions the company favorably as it seeks to improve patient outcomes while navigating the complexities of drug development.
With the biopharmaceutical market for dry eye disease projected to be in the billions, OKYO’s commitment to innovative therapies suggests a significant growth potential. As the company progresses through Phase 2 trials for both DED and NCP, positive clinical outcomes could catalyze share price appreciation and attract further institutional interest.
While investors should remain cautious of the inherent risks associated with clinical-stage biotech investments, the mix of innovative drug development and non-dilutive funding strengthens OKYO’s position. Thus, monitoring the progress of OK-101 in clinical trials will be critical. Investors might consider acquiring shares on market dips while keeping an eye on trial results and potential partnerships that could add value. As always, thorough due diligence and risk management should guide investment decisions in such dynamic sectors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that it has received $1.4 million in non-dilutive funding. This significant financial funding strengthens the Company’s ability to advance its innovative pipeline without diluting shareholder value.
The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating NCP, a major unmet medical need.
“Securing $1.4 million in non-dilutive funding marks an important milestone for OKYO Pharma. This financial boost will significantly contribute to our mission of developing groundbreaking treatments for ophthalmic diseases,” commented Dr. Gary S. Jacob, CEO of OKYO Pharma. “Importantly, this funding supports our ability to continue creating value for our shareholders while advancing our clinical programs. We remain committed to driving innovation and delivering solutions that improve patient outcomes.”
The infusion of non-dilutive funding underscores OKYO Pharma’s commitment to maintaining fiscal responsibility while pursuing transformative therapies that address critical unmet medical needs.
About NCP
Neuropathic corneal pain (NCP) is a condition that causes pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but thought to result from nerve damage to the cornea combined with inflammation . NCP, which can exhibit as a severe, chronic, or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating condition.
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of OK-101 within the ocular environment. OK-101 showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial of OK-101 to treat DED, and is presently being evaluated in a randomized, placebo-controlled, double-masked Phase 2 trial to treat 48 NCP patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat NCP and inflammatory DED. In addition to the completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also currently evaluating OK-101 to treat NCP patients in a Phase 2 trial.
For further information, please visit www.okyopharma.com .
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ**
How might the $1.4 million in non-dilutive funding impact the ongoing research initiatives of OKYO Pharma Limited (OKYO) in the development of innovative therapies for conditions like neuropathic corneal pain and dry eye disease?
What strategic advantages does OKYO Pharma Limited (OKYO) gain from focusing its funding allocation on its lead program, OK-101, in light of the significant unmet medical need for treating neuropathic corneal pain (NCP)?
Considering the importance of fiscal responsibility, how does OKYO Pharma Limited (OKYO) plan to utilize the new funding to maintain shareholder value while advancing its clinical programs for ophthalmic diseases?
With OK-101 showing promising results in its Phase 2 trials, what are the next steps for OKYO Pharma Limited (OKYO) in further evaluating the drug's efficacy and safety for both neuropathic corneal pain and dry eye disease treatments?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
0.01% G/L:
$1.68 Last:
16,063 Volume:
$1.70 Open:
